$25.56
+0.82(3.31%)
Mkt Cap $45M
$4.50
$29.35
52-Week Range
At a Glance
AI-generatedPrecipio delivered strong top-line growth and significantly narrowed losses in FY2025, progressing toward operational scale as it targets sustained profitability.
8-K
Precipio, Inc. announced preliminary unaudited financial results for Q4-2025 and fiscal year 2025, reporting revenue of $24.0M for 2025 (30% YoY increase) and $6.7M for Q4-2025 (23% YoY increase), positive Adjusted EBITDA of $0.95M and $1.23M respectively, and positive operating cash flow.$45M
Market Cap
$23M
Revenue
-$1M
Net Income
Employees54
Fundamentals
How The Business Makes Money
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Industry Medical - Diagnostics & Research
Activity
Analyst View
Company Profile
CIK0001043961
ISINUS74019L6020
CUSIP74019L503
Phone203 787 7888
Address4 Science Park, New Haven, CT, 06511, US
SEC EDGAR